August 14, 2019 / 4:57 PM / 4 months ago

U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

Aug 14 (Reuters) - The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

The decision comes two months after a panel of advisers to the FDA voted 14-4 in favor of the drug, pretomanid, in combination with linezolid and Johnson & Johnson's bedaquiline for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below